Five Prime Therapeutics (Five Prime Therapeutics) EV-to-EBITDA : -17.59 (As of May. 24, 2024)

Five Prime Therapeutics EV-to-EBITDA Chart

Five Prime Therapeutics Annual Data
	Trend	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20
EV-to-EBITDA		Get a 7-Day Free Trial					-9.67	-2.33	-0.12	-0.38	-6.54

Five Prime Therapeutics Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
EV-to-EBITDA	Get a 7-Day Free Trial															-0.38	0.08	-1.56	-1.01	-6.54

Competitive Comparison of Five Prime Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Five Prime Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Five Prime Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Five Prime Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Five Prime Therapeutics's EV-to-EBITDA falls into.

Five Prime Therapeutics EV-to-EBITDA Calculation

Five Prime Therapeutics's EV-to-EBITDA for today is calculated as:

Five Prime Therapeutics's current Enterprise Value is $1,529.91 Mil.
Five Prime Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Five Prime Therapeutics  (NAS:FPRX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Five Prime Therapeutics's PE Ratio for today is calculated as:

Five Prime Therapeutics's share price for today is $38.00.
Five Prime Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.290.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Five Prime Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Five Prime Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Five Prime Therapeutics (Five Prime Therapeutics) Business Description